StockData
Context Therapeutics Inc. logo

Context Therapeutics Inc. (CNTX) stock

CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.17+0.01 (+3.07%)

Close on Nov 17, 2026Market cap $15.71MP/E –Yield –

Context Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Context Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$48.73M. For fiscal 2025 it was -$39.70M. The highest annual figure on record is -$2.57M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$39.70M–
FY2024Dec 31, 2024-$29.92M–
FY2023Dec 31, 2023-$25.07M–
FY2022Dec 31, 2022-$15.38M–
FY2021Dec 31, 2021-$10.53M–
FY2020Dec 31, 2020-$2.57M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.97M–
Q1 FY2026Mar 31, 2026-$9.34M–
Q4 FY2025Dec 31, 2025-$13.80M–
Q3 FY2025Sep 30, 2025-$10.61M–
Q2 FY2025Jun 30, 2025-$9.76M–
Q1 FY2025Mar 31, 2025-$5.53M–
Q4 FY2024Dec 31, 2024-$4.31M–
Q3 FY2024Sep 30, 2024-$18.70M–
Q2 FY2024Jun 30, 2024-$3.09M–
Q1 FY2024Mar 31, 2024-$3.82M–
Q4 FY2023Dec 31, 2023-$6.93M–
Q3 FY2023Sep 30, 2023-$6.18M–
Q2 FY2023Jun 30, 2023-$5.29M–
Q1 FY2023Mar 31, 2023-$6.67M–
Q4 FY2022Dec 31, 2022-$3.88M–
Q3 FY2022Sep 30, 2022-$4.05M–
Q2 FY2022Jun 30, 2022-$4.01M–
Q1 FY2022Mar 31, 2022-$3.44M–
Q4 FY2021Dec 31, 2021-$3.09M–
Q3 FY2021Sep 30, 2021-$1.57M–
Q2 FY2021Jun 30, 2021-$5.03M–
Q1 FY2021Mar 31, 2021-$840.32K–
Q4 FY2020Dec 31, 2020-$769.54K–
Q3 FY2020Sep 30, 2020-$651.06K–

More Context Therapeutics figures

See a number that looks wrong?